300143 INKON Life Technology
- 7.65
- -0.17-2.17%
INKON Life Technology News
Inkon Life Technology (300143.SZ): Cumulative expenditure of 47.8567 million yuan to repurchase 5.5907 million shares.
On June 3rd, Gelonhui reported that Inkon Life Technology (300143.SZ) announced that as of May 31, 2024, the company repurchased 5,590,652 shares of its own stock through a share repurchase dedicated securities account using centralized bidding trading method, accounting for 0.87% of the company's current total share capital (calculated based on the company's total share capital of 642,167,010 shares after the close of trading on June 3, 2024). The highest and lowest transaction prices for the repurchase were 8.90 yuan/share and 8.09 yuan/share, respectively, and the total transaction amount was RMB 47,856,696.96 (excluding transaction fees).
Yingkang Life (300143.SZ): As of May 20, 2024, the total number of shareholders of the company was 16,540
Gelonghui May 24 | Yingkang Life (300143.SZ) said on the investor interactive platform that as of May 20, 2024, the total number of shareholders of the company was 16,540.
Express News | Yingkang Life: Controlling shareholders plan to increase their holdings by 50 million yuan to 80 million yuan
INKON Life Technology Co., Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
It's been a good week for INKON Life Technology Co., Ltd. (SZSE:300143) shareholders, because the company has just released its latest yearly results, and the shares gained 6.7% to CN¥7.95. It w
Express News | Yingkang Life: First quarter revenue of 416 million yuan, up 15.17% year on year.
Dongwu Securities released a research report on April 25 stating that Yingkang Life (300143.SZ) was given a purchase rating. The main reasons for the rating include: 1) the medical service sector has achieved steady and high-quality development, and Frien
Dongwu Securities released a research report on April 25 stating that Yingkang Life (300143.SZ) was given a purchase rating. The main reasons for the rating include: 1) the medical service sector has achieved steady and high-quality development, and Friendship Hospital and Guangci Hospital have performed well; 2) the medical device sector has expanded through mergers and acquisitions, and the scale of revenue has grown rapidly. (Mainichi Keizai Shimbun)
Yingkang Life (300143.SZ): Net profit of 26.22,900 yuan in the first quarter decreased by 33.69% year-on-year
Gelonghui, April 25 | Yingkang Life (300143.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 416 million yuan, up 15.17% year on year; net profit attributable to shareholders of listed companies was 26.22,900 yuan, down 33.69% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 238.246 million yuan, down 38.55% year on year; basic earnings per share were 0.0410 yuan.
Yingkang Life (300143) 2023 Annual Report Review: Outstanding performance starts high-quality development
Event: The company released its 2023 annual report: the company achieved operating income of 1,471 billion yuan (+27.20%), net profit to mother of 100 million yuan (+116.85% year over year), net profit not attributable to mother
Huaan Securities released a research report on April 23 stating that Yingkang Life (300143.SZ) was given a purchase rating. The main reasons for the rating include: 1) strong recovery in performance and overall improvement in profitability; 2) two-wheel d
Huaan Securities released a research report on April 23 stating that Yingkang Life (300143.SZ) was given a purchase rating. The main reasons for the rating include: 1) strong recovery in performance and overall improvement in profitability; 2) two-wheel drive in the medical service & equipment sector, and the company's high-quality development has reached a new level. (Mainichi Keizai Shimbun)
China Post Securities released a research report on April 23 stating that Yingkang Life (300143.SZ) was given a purchase rating. The main reasons for the rating include: 1) rapid growth in revenue and profit, and steady increase in profitability; 2) the m
China Post Securities released a research report on April 23 stating that Yingkang Life (300143.SZ) was given a purchase rating. The main reasons for the rating include: 1) rapid growth in revenue and profit, and steady increase in profitability; 2) the medical service and device sectors have achieved excellent results, and high quality development trends are prominent; 3) Continued enhancement of the core competitiveness of the service and device sector, with sufficient long-term growth drivers. (Mainichi Keizai Shimbun)
Yingkang Life (300143:) has shown impressive results in 23 years, and the device business may continue to grow rapidly
Revenue/net profit recovered strongly. We are optimistic that the equipment business will continue to grow at a high rate in 24, Yingkang Life announced that it achieved revenue of 1.47 billion yuan (+27.2% yoy) in 2023 and net profit of 100 million yuan (year-on-year increase)
Yingkang Life (300143.SZ) reported 2023 results, with net profit of 100 million yuan, turning a year-on-year loss into a profit
Yingkang Life (300143.SZ) released its 2023 annual report. The company achieved operating income of 14 during the reporting period...
Yingkang Life (300143.SZ): A total cost of 2.6973 million yuan to buy back 309,300 shares
Gelonghui, March 4, 丨 Yingkang Life (300143.SZ) announced that as of February 29, 2024, the company had repurchased 309,300 shares of the company's shares through a special stock repurchase account, accounting for 0.05% of the company's current total share capital (calculated based on the company's total share capital of 642,167,010 shares after closing on March 4, 2024). The highest price of the repurchase transaction was 8.82 yuan/share, the lowest price was 8.55 yuan/share, and the total transaction amount was RMB 2.6973 million (excluding transaction fees).
Yingkang Life (300143.SZ): Initial repurchase of 309,300 shares involving 2.6973 million yuan
Gelonghui, Feb. 27丨Yingkang Life (300143.SZ) announced that on February 27, 2024, for the first time, the company repurchased 309,300 shares of the company's shares through a special stock repurchase account, accounting for 0.05% of the company's current total share capital (calculated based on the company's total share capital of 642,167,010 shares after closing on February 27, 2024). The highest price of the repurchase transaction was 8.82 yuan/share, the lowest price was 8.55 yuan/share, and the total transaction amount was RMB 2,6972.97 million (excluding transaction fees).
Yingkang Life (300143.SZ): As of February 20, 2024, the total number of shareholders of the company was 1,7050
Gelonghui, February 22丨Yingkang Life (300143.SZ) said on the interactive platform that as of February 20, 2024, the total number of shareholders of the company was 17,050.
Yingkang Life (300143.SZ): As of January 31, 2024, the total number of shareholders of the company was 17,162
Gelonghui, Feb. 7 | Yingkang Life (300143.SZ) said on the interactive platform that as of January 31, 2024, the total number of shareholders of the company was 17,162.
Express News | Yingkang Life: Plans to repurchase the company's shares for 40 million yuan to 80 million yuan
Yingkang Life (300143.SZ): 2023 pre-profit of 97 million yuan to 125 million yuan, reversing losses year-on-year
Gelonghui, January 26 | Yingkang Life (300143.SZ) announced its 2023 annual results forecast. Net profit attributable to shareholders of listed companies during the reporting period was 9700.00 million yuan - 125.0 million yuan, loss of 595.9181 million yuan for the same period of the previous year; net profit profit after deducting non-recurring profit and loss of 960.000 yuan - 124.0 million yuan, and loss of 596.9825 million yuan for the same period last year. During the reporting period, net profit attributable to shareholders of listed companies turned a loss into a profit compared to the same period of the previous year. The main reason was that the previous year's results were calculated based on goodwill impairment
Yingkang Life (300143.SZ): Received a review inquiry letter from the Shenzhen Stock Exchange regarding the application for an increase
Glonghui December 12丨Yingkang Life (300143.SZ) announced that on December 12, 2023, the company received the “Audit Inquiry Letter on Yingkang Life Technology Co., Ltd.'s application to issue shares to specific targets” (Audit Letter [2023] No. 020155) from the Shenzhen Stock Exchange. The Shenzhen Stock Exchange's issuance and listing review agency reviewed the company's application documents for issuing shares to specific targets, and formed audit questions. In accordance with the requirements of the above inquiry letter, the company will work with relevant intermediaries to implement and submit responses to the inquiry letter in a timely manner. The content of the response will be passed through the Provisional Public Administration
Highlights of A-share midday announcements | A series of plant protection technical improvement projects of Limin Co., Ltd. subsidiaries passed trial production acceptance
Gelonghui, November 24 | ① Limin Co., Ltd.: Limin Chemical, a wholly-owned subsidiary, recently completed the installation and commissioning of equipment that produces 500 tons of cyclic sulfonone in a year and 1,000 tons of nitrosulfonone in a year in a series of technical improvement projects. The trial production plan has been reviewed and approved by experts. ② Yingkang Life: Applications to issue shares to specific targets were accepted by the Shenzhen Stock Exchange.
Analysis
Price Target
No Data
